Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for treating moderate to severe atopic dermatitis:
- Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (2024) NICE technology appraisal guidance 986
- Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (2022) NICE technology appraisal guidance 814
- Baricitinib for treating moderate to severe atopic dermatitis (2021) NICE technology appraisal guidance 681
- Dupilumab for treating moderate to severe atopic dermatitis (2018) NICE technology appraisal guidance 534
This page was last updated: